BioStock: Oncoinvent gets IND clearance for both lead indications

Oncoinvent has secured IND clearance from the FDA for both of the planned phase IIb clinical trials with Radspherin in patients with peritoneal carcinomatosis from colorectal cancer and ovarian cancer. This marks a milestone allowing Oncoinvent to clinically advance Radspherin and expand to the US landscape. BioStock reached out to CEO Anders Månsson to find out more about the development strategy.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/11/oncoinvent-gets-ind-clearance-for-both-lead-indications/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se